inhibitor of nuclear factor kappa B kinase subunit betaGenealiases: IKK-2 · IKK-beta · IKK2 · IKKB · IMD15 · IMD15A
Q-omics provides the consensus-scored IKBKB profile across patient tissues and cancer cell-line models. IKBKB expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, IKBKB is differentially expressed in 10, with the highest sampling consensus in COAD. Additionally, IKBKB RNA expression shows 20,140 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight BLCA, COAD, and KIRP as cancer lineages where IKBKB shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IKBKB — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IKBKB survival associations across molecular data types. IKBKB RNA expression shows survival associations in the most cancer types (23), followed by mutation status (5) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IKBKB RNA expression–survival associations across cancer types. High IKBKB expression shows unfavorable associations in KICH, UCEC and LGG, but favorable associations in BLCA, HNSC and SKCM. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for IKBKB RNA expression.
This table summarizes IKBKB tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 7. The strongest signals are observed in COAD for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for IKBKB. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IKBKB shows lower tumor expression in THCA and KICH and higher tumor expression in COAD, LIHC, CHOL and STAD. The COAD box plot shows higher IKBKB RNA expression in tumor versus normal tissue (log2 FC = +0.653, t-test p < 0.001).
This table shows molecular features associated with IKBKB in patient tissues and cancer cell lines. In patient samples, IKBKB shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, IKBKB RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and UPPER_AERODIGESTIVE_TRACT.
